WHAT IS CLAIMED IS:

1. An isolated antibody that
is fully human and specifically binds to a hLIGHT epitope,wherein the antibody comprises:

(a) a VH CDR1, VH CDR2 and VH CDR3 of an antibody produced by a hybridoma having ATCC Accession NO. PTA-7819 and
(b) a VL CDR1, VL CDR2 and VL CDR3 of an antibody produced by a hybridoma having ATCC Accession No. PTA-7819.

2. An isolated antibody that is fully human and specifically binds to a hLIGHT epitope, wherein the antibody comprises:

(a) a heavy chain variable region comprising:
(1) a VH CDR1 of SEQ ID NO:20;
(2) a VH CDR2 of SEQ ID NO:21; and
(3) a VH CDR3 of SEQ ID NO:22;

and

(b) a light chain variable region comprising:
(1) a VL CDR1 of SEQ ID NO: 93, a VL CDR2 of SEQ ID NO: 96 and a VL CDR3 of SEQ ID NO: 99, selected from the group consisting of SEQ ID NOs: 35, 93, 94 and 95;
(2) a VL CDR1 of SEQ ID NO: 35, a VL CDR2 of SEQ ID NO: 36 and a VL CDR3 of SEQ ID NO: 37, CDR2 selected from the group consisting of SEQ ID NOs: 96, 36, 97 and 98; and
(3) a VL CDR1 of SEQ ID NO: 94, a VL CDR2 of SEQ ID NO: 97 and a VL CDR3 of SEQ ID NO: 100, or
(4) a VL CDR1 of SEQ ID NO: 95, a VL CDR2 of SEQ ID NO: 98 and a VL CDR3 of SEQ ID NO: 101.
CDR3 selected from the group consisting of SEQ ID NOs 99, 37,100 and 101.

3. The antibody of claim 1 or 2, wherein the antibody is an antagonist antibody.

4. The antibody of claim 3,

wherein the antibody competes with HVEM, LTβR, or a fusion protein thereof, for binding to cell surface-expressed hLIGHT or soluble hLIGHT, or

wherein the antibody partially or completely inhibits binding of HVEM, LTBR, DcR3, or any combination thereof, to cell surface-expressed hLIGHT or soluble hLIGHT, or

wherein the antibody partially or completely inhibits hLIGHT-mediated secretion of CCL20, IL-8, RANTES, or any combination thereof, from a cell having a cell surface-expressed hLIGHT receptor.

5. The antibody of claim 1 or 2, wherein the antibody comprises (a) a VH of an antibody produced by a hybridoma having ATCC Accession NO. PTA-7819; and/or (b) a VL of an antibody produced by the hybridoma having ATCC Accession No. PTA-7819.

6. The antibody of claim 1 or 2, wherein the isolated antibody is an antibody produced by the hybridoma of ATCC Accession No. PTA-7819.

7. The antibody of claim 1 or 2, wherein the antibody comprises:

(a) a heavy chain variable region (VH) having the 20-141 residues of amino acid sequence depicted in SEQ ID NOs:4; and/or

(b) a light chain variable region (VL) having the 23-129 residues of the amino acid sequence depicted in SEQ ID NO: 9, the 23-129 residues of the amino acid sequence depicted in SEQ NO: 90, the 23-129 residues of the amino acid sequence depicted in SEQ ID NO: 91 or the 21-126 residues of the amino acid sequence depicted in SEQ ID NO: 92.~~the amino acid sequence depicted in any one of SEQ ID NOs:9, 90, 91 or 92~~